Characterizing the involvement of the nuclear factorkappa b (NFκB) transcription factor in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 1811-1816

  Dror, Rinat ^a   Lederman, Michal ^a   Umezawa, Kazuo ^b   Barak, Vivian ^a   Pe'er, Jacob ^a   Chowers, Itay ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CASPASE 3; DEHYDROXYMETHYLEPOXYQUINOMICIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; METHYLENE BLUE; NUCLEAR FACTOR KAPPA B INDUCING KINASE; PROTEIN P100; PROTEIN P105; PROTEIN P52; TETRAZOLIUM; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; 4(2' AMINOETHYL)AMINO 1,8 DIMETHYLIMIDAZO(1,2 A)QUINOXALINE; 4(2'-AMINOETHYL)AMINO-1,8-DIMETHYLIMIDAZO(1,2-A)QUINOXALINE; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; IMIDAZOLE DERIVATIVE; MESSENGER RNA; QUINOXALINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHOROID; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; UVEA MELANOMA; WESTERN BLOTTING; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; LIVER TUMOR; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; UVEA TUMOR;

APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; CYCLOHEXANONES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMIDAZOLES; KI-67 ANTIGEN; LIVER NEOPLASMS; MELANOMA; NF-KAPPA B; QUINOXALINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 77951239640     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3392     Document Type: Article

References (38)

1. Damato B. Developments in the management of uveal melanoma. Clin Exp Ophthalmol. 2004;32:639-647.
2. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006;46:133-149.
3. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151-166.
4. Kincaid MC. Uveal melanoma. Cancer Control. 1998;5:299-309.
5. Meir T, Dror R, Yu X, et al. Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48:4890-4896.
6. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18: 2195-2224.
7. Moynagh PN. The NF-κB pathway. J Cell Sci. 2005;118:4589-4592.
8. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-κB. Cell Death Differ. 2006;13:759-772.
9. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.
10. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001;7:401-409.
11. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
12. Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758-6780.
13. Pacifico F, Leonardi A. NF-κB in solid tumors. Biochem Pharmacol. 2006;72:1142-1152.
14. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441:431-436.
15. Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 2005;229:157-169.
16. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N. Constitutive nuclear factor-κB activity is crucial for human retinoblastoma cell viability. Am J Pathol. 2002;161:2229-2240.
17. Matsumoto N, Ariga A, To-e S, et al. Synthesis of NFκB activation inhibitors derived from epoxyquinomicin. C Bioorg Med Chem Lett. 2000;10:865-869.
18. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 2006;97:990-995.
19. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of -κB kinase and induces apoptosis in melanoma: involvement of nuclear factor-κB and mitochondria pathways. Clin Cancer Res. 2006;12:950-960.
20. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I κ B kinase that binds at an allosteric site of the enzyme and blocks NF-κ B-dependent transcription in mice. J Biol Chem. 2003;278:1450-1456.
21. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007; 109:2700-2707.
22. Ueda Y, Richmond A. NF-κB activation in melanoma. Pigment Cell Res. 2006;19:112-124.
23. Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33-40.
24. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:505-510.
25. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-1421.
26. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary bodymelanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1-6.
27. de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996;234:34-42.
28. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999;9:445-450.
29. Orlowski RZ, Baldwin AS Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med. 2002;8:385-389.
30. Gilmore TD, Herscovitch M. Inhibitors of NFκB signaling: 785 and counting. Oncogene. 2006;25:6887-6899.
31. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738-747.
32. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007;13:1076-1082.
33. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of I κ B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 2003;48:2652-2659.
34. Watanabe M, Dewan MZ, Okamura T, et al. A novel NFκ inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer. 2005;114:32-38.
35. Matsumoto G, Namekawa J, Muta M, et al. Targeting of nuclear factor-κB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287-1293.
36. Watanabe M, Ohsugi T, Shoda M, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005;106:2462-2471.
37. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-κB signaling module. Oncogene. 2006;25:6706-6716.
38. Balducci L. Molecular insight in cancer treatment and prevention. Int J Biochem Cell Biol. 2007;39:1329-1336.